- Home
- AIRI vs NLSP Comparison
AIRI vs NLSP Comparison
Compare AIRI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- NLSP
- Stock Information
- Founded
- AIRI 1979
- NLSP 2015
- Country
- AIRI United States
- NLSP Switzerland
- Employees
- AIRI N/A
- NLSP N/A
- Industry
- AIRI Military/Government/Technical
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- NLSP Health Care
- Exchange
- AIRI Nasdaq
- NLSP Nasdaq
- Market Cap
- AIRI 15.2M
- NLSP 12.4M
- IPO Year
- AIRI N/A
- NLSP 2021
- Fundamental
- Price
- AIRI $3.22
- NLSP $1.99
- Analyst Decision
- AIRI
- NLSP
- Analyst Count
- AIRI 0
- NLSP 0
- Target Price
- AIRI N/A
- NLSP N/A
- AVG Volume (30 Days)
- AIRI 67.0K
- NLSP 203.0K
- Earning Date
- AIRI 08-14-2025
- NLSP 10-17-2025
- Dividend Yield
- AIRI N/A
- NLSP N/A
- EPS Growth
- AIRI N/A
- NLSP N/A
- EPS
- AIRI N/A
- NLSP N/A
- Revenue
- AIRI $52,277,000.00
- NLSP N/A
- Revenue This Year
- AIRI N/A
- NLSP N/A
- Revenue Next Year
- AIRI $4.99
- NLSP N/A
- P/E Ratio
- AIRI N/A
- NLSP N/A
- Revenue Growth
- AIRI N/A
- NLSP N/A
- 52 Week Low
- AIRI $2.80
- NLSP $1.30
- 52 Week High
- AIRI $7.41
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- AIRI 49.40
- NLSP 40.19
- Support Level
- AIRI $3.13
- NLSP $2.03
- Resistance Level
- AIRI $3.37
- NLSP $2.29
- Average True Range (ATR)
- AIRI 0.12
- NLSP 0.18
- MACD
- AIRI 0.02
- NLSP -0.06
- Stochastic Oscillator
- AIRI 73.68
- NLSP 11.92
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.